# HysensBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hysensbio-co

- Industry: Healthcare Specialists
- Headquarters: Gwacheon, South Korea
- Website: www.hysensbio.com
- Total disclosed funding: $19M
- Latest round: Series C (May 6, 2021)
- Investors on record: 9

## About

HysensBio Co., Ltd., based in South Korea, develops innovative therapeutic solutions utilizing cell activation and anti-aging technologies to address complex dental health issues.Founded in 2016 in Gwacheon, South Korea, HysensBio Co., Ltd. focuses on transforming dental treatments. The company has successfully engaged in four deals, with the most recent being a Pre-IPO funding round on July 12, 2023, raising KRW 11.3 billion from various investors, including Cape Investment & Securities and ORION HOLDINGS. The founder, Joo-cheol Park, has a history of entrepreneurship that contributes to HysensBio's direction and strategies. The firm has raised a total of KRW 11.3 billion, with a current company valuation of KRW 100 billion.HysensBio specializes in developing therapeutic solutions, including KH-001, KH-002, and HBO-001, which target odontoblasts and periodontal ligament fibroblasts. These products seek to treat dental issues such as dentin hypersensitivity and periodontal diseases, catering primarily to dental clinics and healthcare providers in South Korea and other growing Asian markets.In 2024, HysensBio reported revenue of KRW 59,387.3 million, with an EBITDA amounting to -KRW 6,603.6 million. The company's revenue model relies on B2B partnerships with dental clinics, facilitating access to their therapeutic products, including the IND-approved KH-001 for clinical trials for addressing dentin hypersensitivity.Following the funding round on July 12, 2023, which resulted in KRW 11.3 billion raised for Pre-IPO preparations, HysensBio aims to expand its product line with new offerings that enhance their existing therapeutic solutions. The company is also targeting expansion into new markets across Asia by the end of 2024, leveraging recent investments to support these growth initiatives and the anticipated IPO listing with the Korea Exchange.

## Funding rounds

- Series C, May 6, 2021, $12M — Korea Investment & Securities, WOORI Venture Partners, Korea Investment Partners, Time Folio Asset Management, Harang Invest, DS Asset Management
- Series B, May 25, 2019, $5.9M — Korea Investment Partners, Mirae Asset Securities, Samsung Securities, Time Folio Asset Management, DAYLI Partners
- Series A, Mar 20, 2018, $1.9M — Korea Investment Partners

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B, Series C
- Mirae Asset Securities (https://capitalatlas.ai/funds/mirae-asset-securities) — Series B
- Samsung Securities — Series B
- Time Folio Asset Management — Series B, Series C
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series C
- Harang Invest (https://capitalatlas.ai/funds/harang-invest) — Series C
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series C